BeMe is a mobile‑first mental‑wellness platform that provides daily mood tracking, AI‑driven content recommendations, and on‑demand text‑based coaching from licensed professionals for users aged 13‑24. The app uses end‑to‑end encryption and HIPAA‑aligned storage, offers 24/7 crisis‑support links, and integrates with health insurers and employer benefit programs to deliver confidential, ad‑free support.

Be Me Health is a mobile platform that provides personalized coaching and mood tracking tools to support the mental health of teens and young adults. The app creates a confidential environment for users to explore their emotions, access tailored resources, and connect with real-time coaches, addressing the pervasive issue of youth loneliness and emotional distress.

ByHeart produces an FDA-registered infant formula featuring a patented protein blend that closely mimics the composition of breast milk, utilizing organic, grass-fed whole milk for enhanced nutrient absorption and easier digestion. The formula addresses common infant feeding challenges by promoting softer stools, reduced spit-up, and improved weight gain, all backed by clinical research.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.

Elvance is a Salesforce Native AI platform that enhances PreSales and Opportunity Management by utilizing AI-driven technical scorecards for risk assessment and product gap analysis. It improves forecasting accuracy and technical win rates by providing integrated resource management and analytics, enabling sales teams to optimize their performance and collaboration.

Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.

One Health Company utilizes genomic testing and AI-driven precision medicine to identify targeted therapies for canine cancer, leveraging the largest proprietary cancer dataset from over 2,100 dogs. This approach addresses the high failure rate of traditional cancer treatments by providing veterinarians with data-driven insights to optimize treatment plans for individual dogs.

FIRE1 is developing novel therapeutic devices aimed at enhancing patient outcomes through targeted delivery mechanisms. The startup addresses the need for more effective treatment options in the medical device sector, focusing on improving therapeutic efficacy and patient compliance.

Heavy develops robotic solutions specifically designed for construction, mining, and farming, utilizing autonomous machinery to improve operational safety. The company's technology addresses the high risk of accidents in these industries by automating hazardous tasks and reducing human exposure to dangerous environments.

Kallyope develops oral small-molecule therapeutics targeting metabolic, neurological, and gastrointestinal diseases by utilizing its Klarity™ platform to explore gut-brain signaling pathways. The company focuses on conditions such as obesity, diabetes, migraines, and celiac disease, aiming to provide effective and well-tolerated treatment options.

Kojin develops targeted small-molecule therapeutics that modulate ferroptosis, a form of regulated cell death, to treat various cancers and degenerative diseases. By leveraging a drug discovery platform that integrates computational chemistry and mechanism-driven pharmacology, Kojin aims to address the limitations of existing therapies for ferroptosis-sensitive tumors.

Larkspur Bioscience develops small molecule therapeutics designed to target cancer cell fitness pathways. These compounds decrease cancer cell fitness, making tumors susceptible to intrinsic and immune-mediated killing mechanisms. The company focuses on overcoming resistance limitations associated with current targeted and immune therapies.

Leyden Labs develops nasal sprays that deliver antibodies directly to the nasal mucosa to provide immediate protection against respiratory viruses, preventing initial infections and onward transmission. Their technology targets conserved epitopes across viral families, offering broad protection against existing and emerging strains, regardless of an individual's immune history.

This startup offers a neuroscience-based application that analyzes user experiences to map neurological reward systems. By reflecting on users' actions, emotions, and memories, the platform enhances cognitive functions such as intelligence, creativity, and empathy, promoting healthier and more fulfilling lives.

Mesodyne has developed the LightCell, a compact power generator that utilizes solid-state power conversion to achieve over 10 times the energy density of lithium-ion batteries while operating silently and with minimal maintenance. This multi-fuel generator can efficiently convert gasoline, diesel, or jet fuel, providing reliable, long-endurance power for portable applications such as autonomous vehicles and sensors in remote or extreme environments.

Noetik develops frontier AI models trained on extensive multimodal tumor data to predict individual patient responses to cancer treatments. This platform enhances clinical trial enrichment by accurately identifying likely responders for specific therapies. The technology aims to improve drug positioning and accelerate the discovery of novel, human-relevant oncology targets.

Paratus Sciences develops human therapeutics by studying the unique evolutionary adaptations found in bats. The company utilizes a discovery platform merging genomics and informatics to identify promising therapeutic targets from bat biology. This research focuses on creating novel treatments for immunological, inflammatory, and cardiometabolic conditions.

PathAI develops AI-powered pathology technology that enhances diagnostic accuracy by providing pathologists with advanced image management and case management tools. The platform improves patient outcomes by streamlining laboratory workflows and facilitating biomarker discovery for drug development.

Satellite Bio develops Tissue Therapeutics that utilize expanded, mature hepatocyte cells for the treatment of liver dysfunction. Their Satellite Adaptive Tissue Platform enables the precise delivery and durable engraftment of these living cells to restore critical organ function.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Seismic Therapeutic develops machine-learning algorithms specifically designed for biologics drug discovery in the field of immunology, focusing on autoimmune diseases. Their IMPACT platform enhances the efficiency of identifying and optimizing novel therapeutic candidates, addressing the slow and costly traditional drug development processes.

UpDoc provides a Remote Patient Intervention (RPI) platform that uses agentic AI under physician supervision to deliver proactive, evidence-based care between clinical visits. This system continuously monitors patients, drives timely engagement, and triggers precise clinical interventions to improve chronic disease metrics and medication adherence. The platform enables providers to scale high-touch, personalized care economically while achieving durable patient outcomes.

Zag Bio creates thymus‑targeted bifunctional antibodies that attach disease‑specific self‑antigens to an engineered Fc region, delivering them to thymic antigen‑presenting cells to eliminate autoreactive T‑cell clones and induce antigen‑specific regulatory T cells. The resulting Tregs migrate to affected tissues, providing localized immune tolerance without systemic immunosuppression and enabling disease‑modifying therapy for a range of autoimmune disorders. The platform is made available to pharmaceutical, biotechnology, and academic partners developing autoimmune treatments.